nach oben

Discover Oncology

Erschienen in:

28.10.2016 | Original Paper

Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts

verfasst von: Shawna B. Matthews, Carol A. Sartorius

Erschienen in: Discover Oncology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

The vast majority of breast cancers are positive for estrogen receptor (ER) and depend on estrogens for growth. These tumors are treated with a variety of ER-targeted endocrine therapies, although eventual resistance remains a major clinical problem. Other steroid hormone receptors such as progesterone receptor (PR) and androgen receptor (AR) are emerging as additional prospective targets in breast cancer. The fundamental mechanism of action of these steroid receptors in gene regulation has been defined mainly by several breast cancer cell lines that were established in the late 1970s. More recently, breast cancer patient-derived xenografts (PDX) have been developed by multiple groups at institutions in several countries. These new models capture the large degree of heterogeneity between patients and within tumors and promise to advance our understanding of steroid hormone receptor positive breast cancer and endocrine resistance. Unfortunately, steroid hormone receptor positive breast cancers are much more difficult than their receptor negative counterparts to establish into sustainable PDX. Herein we discuss the derivation of steroid hormone receptor positive breast cancer PDX, several pitfalls in their genesis, and their utility in preclinical and translational steroid hormone receptor research.

Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29CrossRefPubMed

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752CrossRefPubMed

Prat A, Perou CM (2011) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5(1):5–23CrossRefPubMed

Jordan VC (2006) Tamoxifen (Ici46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol 147(Suppl 1):S269–S276PubMedPubMedCentral

Obiorah I, Jordan VC (2011) Progress in endocrine approaches to the treatment and prevention of breast cancer. Maturitas 70(4):315–321CrossRefPubMedPubMedCentral

Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9(9):631–643CrossRefPubMed

Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62:233–247CrossRefPubMedPubMedCentral

Clarke R (1996) Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Breast Cancer Res Treat 39(1):69–86CrossRefPubMed

Outzen HC, Custer RP (1975) Growth of human normal and neoplastic mammary tissues in the cleared mammary fat pad of the nude mouse. J Natl Cancer Inst 55(6):1461–1466PubMed

10.

Rae-Venter B, Reid LM (1980) Growth of human breast carcinomas in nude mice and subsequent establishment in tissue culture. Cancer Res 40(1):95–100PubMed

11.

Gronemeyer H, Gustafsson JA, Laudet V (2004) Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3(11):950–964CrossRefPubMed

12.

Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM (1995) The nuclear receptor superfamily: the second decade. Cell 83(6):835–839CrossRefPubMed

13.

Hagan CR, Lange CA (2014) Molecular determinants of context-dependent progesterone receptor action in breast cancer. BMC Med 12:32CrossRefPubMedPubMedCentral

14.

McNamara KM, Moore NL, Hickey TE, Sasano H, Tilley WD (2014) Complexities of androgen receptor signalling in breast cancer. Endocr Relat Cancer 21(4):T161–T181CrossRefPubMed

15.

Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD, D’Santos C, Robinson JL, Silva G, Launchbury R, Perou CM, Stingl J, Caldas C, Tilley WD, Carroll JS (2015) Progesterone receptor modulates eralpha action in breast cancer. Nature 523(7560):313–317CrossRefPubMedPubMedCentral

16.

Singhal H, Greene ME, Tarulli G, Zarnke AL, Bourgo RJ, Laine M, Chang YF, Ma S, Dembo AG, Raj GV, Hickey TE, Tilley WD, Greene GL (2016) Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer. Sci Adv 2(6):e1501924CrossRefPubMedPubMedCentral

17.

Stoll BA (1967) Progestin therapy of breast cancer: comparison of agents. Br Med J 3(5561):338–341CrossRefPubMedPubMedCentral

18.

van Veelen H, Willemse PH, Tjabbes T, Schweitzer MJ, Sleijfer DT (1986) Oral high-dose medroxyprogesterone acetate versus tamoxifen. a randomized crossover trial in postmenopausal patients with advanced breast cancer. Cancer 58(1):7–13CrossRefPubMed

19.

Muss HB, Cruz JM (1992) High-dose progestin therapy for metastatic breast cancer. Ann Oncol 3(Suppl 3):15–20CrossRefPubMed

20.

Muss HB, Case LD, Atkins JN, Bearden JD 3rd, Cooper MR, Cruz JM, Jackson DV Jr, O’Rourke MA, Pavy MD, Powell BL et al (1994) Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a piedmont oncology association study. J Clin Oncol 12(8):1630–1638PubMed

21.

Fels E (1944) Treatment of breast cancer with testosterone propionate. J Clin Endocrinol 4(121)

22.

Adair FE, Herrmann JB (1946) The use of testosterone propionate in the treatment of advanced carcinoma of the breast. Ann Surg 123:1023–1035CrossRefPubMedCentral

23.

Herrmann JB, Adair FE (1946) The effect of testosterone propionate on carcinoma of the female breast with soft tissue metastases. J Clin Endocrinol Metab 6(6):769–775CrossRefPubMed

24.

Pan D, Kocherginsky M, Conzen SD (2011) Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res 71(20):6360–6370CrossRefPubMedPubMedCentral

25.

Kach J, Conzen SD, Szmulewitz RZ (2015) Targeting the glucocorticoid receptor in breast and prostate cancers. Sci Transl Med 7(305):305ps319CrossRef

26.

Abduljabbar R, Negm OH, Lai CF, Jerjees DA, Al-Kaabi M, Hamed MR, Tighe PJ, Buluwela L, Mukherjee A, Green AR, Ali S, Rakha EA, Ellis IO (2015) Clinical and biological significance of glucocorticoid receptor (Gr) expression in breast cancer. Breast Cancer Res Treat 150(2):335–346CrossRefPubMed

27.

Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall BA, Cai Y, Conzen SD (2013) Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res 19(22):6163–6172CrossRefPubMed

28.

Regan Anderson TM, Ma SH, Raj GV, Cidlowski JA, Helle TM, Knutson TP, Krutilina RI, Seagroves TN, Lange CA (2016) Breast tumor kinase (Brk/Ptk6) is induced by hif, glucocorticoid receptor, and Pelp1-mediated stress signaling in triple-negative breast cancer. Cancer Res 76(6):1653–1663CrossRefPubMed

29.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795CrossRefPubMedPubMedCentral

30.

Tong D, Schuster E, Seifert M, Czerwenka K, Leodolte S, Zeillinger R (2002) Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines. Breast Cancer Res Treat 71(3):249–255CrossRefPubMed

31.

Haldosen LA, Zhao C, Dahlman-Wright K (2014) Estrogen receptor beta in breast cancer. Mol Cell Endocrinol 382(1):665–672CrossRefPubMed

32.

Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC (2003) Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 63(10):2434–2439PubMedPubMedCentral

33.

McGuire WL (1978) Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5(4):428–433PubMed

34.

Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM (2011) Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the nurses’ health study. Mod Pathol 24(7):924–931CrossRefPubMedPubMedCentral

35.

Kuenen-Boumeester V, Van der Kwast TH, Claassen CC, Look MP, Liem GS, Klijn JG, Henzen-Logmans SC (1996) The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 32A(9):1560–1565CrossRefPubMed

36.

Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R (2010) Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 23(2):205–212CrossRefPubMed

37.

Vilasco M, Communal L, Mourra N, Courtin A, Forgez P, Gompel A (2011) Glucocorticoid receptor and breast cancer. Breast Cancer Res Treat 130(1):1–10CrossRefPubMed

38.

Leo JC, Guo C, Woon CT, Aw SE, Lin VC (2004) Glucocorticoid and mineralocorticoid cross-talk with progesterone receptor to induce focal adhesion and growth inhibition in breast cancer cells. Endocrinology 145(3):1314–1321CrossRefPubMed

39.

Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Dieras V, Poupon MF (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13(13):3989–3998CrossRefPubMed

40.

Cottu P, Marangoni E, Assayag F, de Cremoux P, Vincent-Salomon A, Guyader C, de Plater L, Elbaz C, Karboul N, Fontaine JJ, Chateau-Joubert S, Boudou-Rouquette P, Alran S, Dangles-Marie V, Gentien D, Poupon MF, Decaudin D (2012) Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts. Breast Cancer Res Treat 133(2):595–606CrossRefPubMed

41.

Bergamaschi A, Hjortland GO, Triulzi T, Sorlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O (2009) Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol 3(5–6):469–482CrossRefPubMed

42.

DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm AL (2011) Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17(11):1514–1520CrossRefPubMedPubMedCentral

43.

Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA (2012) Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat 135(2):415–432CrossRefPubMed

44.

Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME, Smyth GK, Christie M, Phillipson LJ, Burns CJ, Mann GB, Visvader JE, Lindeman GJ (2013) Targeting Bcl-2 with the Bh3 mimetic Abt-199 in estrogen receptor-positive breast cancer. Cancer Cell 24(1):120–129CrossRefPubMed

45.

Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, Mao S, Pavlick AC, Froehlich AM, Wu MF, Tsimelzon A, Hilsenbeck SG, Chen ES, Zuloaga P, Shaw CA, Rimawi MF, Perou CM, Mills GB, Chang JC, Lewis MT (2013) A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 73(15):4885–4897CrossRefPubMedPubMedCentral

46.

Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, Harrison M, Mooney T, McMichael JF, Luo J, Tao Y, Goncalves R, Schlosberg C, Hiken JF, Saied L, Sanchez C, Giuntoli T, Bumb C, Cooper C, Kitchens RT, Lin A, Phommaly C, Davies SR, Zhang J, Kavuri MS, McEachern D, Dong YY, Ma C, Pluard T, Naughton M, Bose R, Suresh R, McDowell R, Michel L, Aft R, Gillanders W, DeSchryver K, Wilson RK, Wang S, Mills GB, Gonzalez-Angulo A, Edwards JR, Maher C, Perou CM, Mardis ER, Ellis MJ (2013) Endocrine-therapy-resistant Esr1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 4(6):1116–1130CrossRefPubMed

47.

Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H, Gelmon K, Chia S, Mar C, Wan A, Laks E, Biele J, Shumansky K, Rosner J, McPherson A, Nielsen C, Roth AJ, Lefebvre C, Bashashati A, de Souza C, Siu C, Aniba R, Brimhall J, Oloumi A, Osako T, Bruna A, Sandoval JL, Algara T, Greenwood W, Leung K, Cheng H, Xue H, Wang Y, Lin D, Mungall AJ, Moore R, Zhao Y, Lorette J, Nguyen L, Huntsman D, Eaves CJ, Hansen C, Marra MA, Caldas C, Shah SP, Aparicio S (2015) Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518(7539):422–426CrossRefPubMed

48.

Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW, Tufegdzic-Vidakovic A, Sammut SJ, Jones L, Provenzano E, Baird R, Eirew P, Hadfield J, Eldridge M, McLaren-Douglas A, Barthorpe A, Lightfoot H, O’Connor MJ, Gray J, Cortes J, Baselga J, Marangoni E, Welm AL, Aparicio S, Serra V, Garnett MJ, Caldas C (2016) A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds. Cell 167(1):260–274, e222CrossRefPubMedPubMedCentral

49.

Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, Viale G, Sotiriou C, Piccart M (2014) Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol 32(25):2794–2803CrossRefPubMed

50.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, Her2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736–750CrossRefPubMedPubMedCentral

51.

Creighton CJ (2012) The molecular profile of luminal B breast cancer. Biologics 6:289–297PubMedPubMedCentral

52.

Petrillo LA, Wolf DM, Kapoun AM, Wang NJ, Barczak A, Xiao Y, Korkaya H, Baehner F, Lewicki J, Wicha M, Park JW, Spellman PT, Gray JW, van’t Veer L, Esserman LJ (2012) Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Breast Cancer Res Treat 135(3):913–922CrossRefPubMed

53.

Levin-Allerhand JA, Sokol K, Smith JD (2003) Safe and effective method for chronic 17beta-estradiol administration to mice. Contemp Top Lab Anim Sci 42(6):33–35PubMed

54.

Guzman RC, Yang J, Rajkumar L, Thordarson G, Chen X, Nandi S (1999) Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy. Proc Natl Acad Sci U S A 96(5):2520–2525CrossRefPubMedPubMedCentral

55.

Sartorius CA, Shen T, Horwitz KB (2003) Progesterone receptors a and B differentially affect the growth of estrogen-dependent human breast tumor xenografts. Breast Cancer Res Treat 79(3):287–299CrossRefPubMed

56.

Borras M, Hardy L, Lempereur F, el Khissiin AH, Legros N, Gol-Winkler R, Leclercq G (1994) Estradiol-induced down-regulation of estrogen receptor. Effect of various modulators of protein synthesis and expression. J Steroid Biochem Mol Biol 48(4):325–336CrossRefPubMed

57.

Cidlowski JA, Muldoon TG (1978) The dynamics of intracellular estrogen receptor regulation as influenced by 17beta-estradiol. Biol Reprod 18(2):234–246CrossRefPubMed

58.

Horwitz KB, McGuire WL (1978) Nuclear mechanisms of estrogen action. Effects of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing. J Biol Chem 253(22):8185–8191PubMed

59.

Read LD, Greene GL, Katzenellenbogen BS (1989) Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors. Mol Endocrinol 3(2):295–304CrossRefPubMed

60.

Cui X, Schiff R, Arpino G, Osborne CK, Lee AV (2005) Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23(30):7721–7735CrossRefPubMed

61.

Agoff SN, Swanson PE, Linden H, Hawes SE, Lawton TJ (2003) Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 120(5):725–731CrossRefPubMed

62.

Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24(29):4660–4671CrossRefPubMed

63.

Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D’Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gomez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK (2014) Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res 16(1):R7CrossRefPubMedPubMedCentral

64.

Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Liu XS, Brown M (2011) Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20(1):119–131CrossRefPubMedPubMedCentral

65.

Ciupek A, Rechoum Y, Gu G, Gelsomino L, Beyer AR, Brusco L, Covington KR, Tsimelzon A, Fuqua SA (2015) Androgen receptor promotes tamoxifen agonist activity by activation of Egfr in Eralpha-positive breast cancer. Breast Cancer Res Treat 154(2):225–237CrossRefPubMedPubMedCentral

66.

Mohammed H, Taylor C, Brown GD, Papachristou EK, Carroll JS, D’Santos CS (2016) Rapid immunoprecipitation mass spectrometry of endogenous proteins (Rime) for analysis of chromatin complexes. Nat Protoc 11(2):316–326CrossRefPubMed

67.

Tentler JJ, Ionkina AA, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JR (2015) P53 family members regulate phenotypic response to aurora kinase A inhibition in triple-negative breast cancer. Mol Cancer Ther 14(5):1117–1129CrossRefPubMedPubMedCentral

68.

Zhang T, Lee YW, Rui YF, Cheng TY, Jiang XH, Li G (2013) Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors. Stem Cell Res Ther 4(3):70CrossRefPubMedPubMedCentral

69.

Behbod F, Kittrell FS, LaMarca H, Edwards D, Kerbawy S, Heestand JC, Young E, Mukhopadhyay P, Yeh HW, Allred DC, Hu M, Polyak K, Rosen JM, Medina D (2009) An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res 11(5):R66CrossRefPubMedPubMedCentral

70.

Sflomos G, Shamsheddin M, Brisken C (2015) An ex vivo model to study hormone action in the human breast. J Vis Exp 95:e52436

71.

Sflomos G, Dormoy V, Metsalu T, Jeitziner R, Battista L, Scabia V, Raffoul W, Delaloye JF, Treboux A, Fiche M, Vilo J, Ayyanan A, Brisken C (2016) A preclinical model for Eralpha-positive breast cancer points to the epithelial microenvironment as determinant of luminal phenotype and hormone response. Cancer Cell 29(3):407–422CrossRefPubMed

72.

Leiter LH (1993) The nod mouse: a model for analyzing the interplay between heredity and environment in development of autoimmune disease. ILAR J 35(1):4–14CrossRef

73.

Baker DG (1998) Natural pathogens of laboratory mice, rats, and rabbits and their effects on research. Clin Microbiol Rev 11(2):231–266PubMedPubMedCentral

74.

Kowalchyk K, Plagemann PG (1985) Cell surface receptors for lactate dehydrogenase-elevating virus on subpopulation of macrophages. Virus Res 2(3):211–229CrossRefPubMed

75.

Plagemann PGWG KF, Swim HE, Chan KKW (1963) Plasma lactic acid dehydrogenase-elevating agent of mice: distribution in tissues and effect on lactic dehydrogenase isozyme patterns. Can J Microbiol 9(1):75–86CrossRef

76.

Liu H, Bockhorn J, Dalton R, Chang YF, Qian D, Zitzow LA, Clarke MF, Greene GL (2011) Removal of lactate dehydrogenase-elevating virus from human-in-mouse breast tumor xenografts by cell-sorting. J Virol Methods 173(2):266–270CrossRefPubMedPubMedCentral

77.

Clarke CL, Graham JD (2012) Non-overlapping progesterone receptor cistromes contribute to cell-specific transcriptional outcomes. PLoS ONE 7(4):e35859CrossRefPubMedPubMedCentral

78.

Creighton CJ, Cordero KE, Larios JM, Miller RS, Johnson MD, Chinnaiyan AM, Lippman ME, Rae JM (2006) Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol 7(4):R28CrossRefPubMedPubMedCentral

79.

Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS (2003) Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144(10):4562–4574CrossRefPubMed

80.

Jacobsen BM, Schittone SA, Richer JK, Horwitz KB (2005) Progesterone-independent effects of human progesterone receptors (Prs) in estrogen receptor-positive breast cancer: Pr isoform-specific gene regulation and tumor biology. Mol Endocrinol 19(3):574–587CrossRefPubMed

81.

Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB (2002) Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 277(7):5209–5218CrossRefPubMed

82.

Dunbier AK, Ghazoui Z, Anderson H, Salter J, Nerurkar A, Osin P, A’Hern R, Miller WR, Smith IE, Dowsett M (2013) Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance. Clin Cancer Res 19(10):2775–2786CrossRefPubMed

83.

Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA (2011) Randomized phase Ii neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline Pam50-based intrinsic subtype—Acosog Z1031. J Clin Oncol 29(17):2342–2349CrossRefPubMedPubMedCentral

84.

Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, Murray J, Murray E, Hampton G, Walker JR, Ho S, Krause A, Evans DB, Dixon JM (2007) Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genomics 17(10):813–826CrossRefPubMed

85.

Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5(8):615–625CrossRefPubMed

86.

Fagan DH, Uselman RR, Sachdev D, Yee D (2012) Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res 72(13):3372–3380CrossRefPubMedPubMedCentral

87.

Lykkesfeldt AE, Madsen MW, Briand P (1994) Altered expression of estrogen-regulated genes in a tamoxifen-resistant and Ici 164,384 and Ici 182,780 sensitive human breast cancer cell line, Mcf-7/Tamr-1. Cancer Res 54(6):1587–1595PubMed

88.

Naundorf H, Becker M, Lykkesfeldt AE, Elbe B, Neumann C, Buttner B, Fichtner I (2000) Development and characterization of a tamoxifen-resistant breast carcinoma xenograft. Br J Cancer 82(11):1844–1850CrossRefPubMedPubMedCentral

89.

Fuqua SA, Gu G, Rechoum Y (2014) Estrogen receptor (Er) alpha mutations in breast cancer: hidden in plain sight. Breast Cancer Res Treat 144(1):11–19CrossRefPubMedPubMedCentral

90.

Oesterreich S, Davidson NE (2013) The search for Esr1 mutations in breast cancer. Nat Genet 45(12):1415–1416CrossRefPubMedPubMedCentral

91.

Holzapfel BM, Wagner F, Thibaudeau L, Levesque JP, Hutmacher DW (2015) Concise review: humanized models of tumor immunology in the 21st century: convergence of cancer research and tissue engineering. Stem Cells 33(6):1696–1704CrossRefPubMed

92.

Morton JJ, Bird G, Keysar SB, Astling DP, Lyons TR, Anderson RT, Glogowska MJ, Estes P, Eagles JR, Le PN, Gan G, McGettigan B, Fernandez P, Padilla-Just N, Varella-Garcia M, Song JI, Bowles DW, Schedin P, Tan AC, Roop DR, Wang XJ, Refaeli Y, Jimeno A (2016) Xactmice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. Oncogene 35(3):290–300CrossRefPubMed

93.

Zhou Q, Facciponte J, Jin M, Shen Q, Lin Q (2014) Humanized Nod-Scid Il2rg−/− mice as a preclinical model for cancer research and its potential use for individualized cancer therapies. Cancer Lett 344(1):13–19CrossRefPubMed

Titel: Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts
verfasst von: Shawna B. Matthews
Carol A. Sartorius
Publikationsdatum: 28.10.2016
Verlag: Springer US
Erschienen in: Discover Oncology / Ausgabe 1/2017
Print ISSN: 1868-8497
Elektronische ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-016-0275-0

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer

miR-15b Inhibits the Progression of Glioblastoma Cells Through Targeting Insulin-like Growth Factor Receptor 1

Thyroid Hormone Controls Breast Cancer Cell Movement via Integrin αV/β3/SRC/FAK/PI3-Kinases

Editorial: Towards Improving the Science of Hormones and Cancer

Effects of Long-Term Vitamin D Supplementation on Regression and Metabolic Status of Cervical Intraepithelial Neoplasia: a Randomized, Double-Blind, Placebo-Controlled Trial

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie